Compare Entegris Inc (ENTG) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Johnson & Johnson — how do they compare? Entegris Inc trades at $162.91 (market cap $22.95B), while Johnson & Johnson trades at $260.71 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 27.3× Entegris Inc's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| ENTG | JNJ | |
|---|---|---|
Market Cap | $22.95B | $626.09B |
Sector | Technology | Health |
52-Week High | $184.00 | $267.24 |
52-Week Low | $68.80 | $174.16 |
Enterprise Value | $26.16B | $654.37B |
Dividend Yield | 0.27% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG is trading at $161.18, up 11.77% with strong momentum following three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI suggests mild overbought conditions. Recent Q2 2026 results exceeded expectations with 11% revenue growth and 42% EPS growth driven by AI-related semiconductor demand. Analyst consensus remains strongly positive with 66.7% buy ratings and a $188.67 price target representing 17% upside potential.
The outlook remains favorable given ENTG's positioning in advanced semiconductor materials, with AI-driven demand providing tailwinds. However, elevated valuation multiples (P/E 75.11) and execution risks in capacity expansion warrant monitoring. The company's improving cash flow generation and strong institutional interest support continued growth, though semiconductor cycle sensitivity presents the primary risk to sustained performance.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
